In a startling about-face, Roche (RHHBY) has agreed to release the recipe for a liquid solution that Dutch laboratories need to run a coronavirus test, after initially refusing to do so and causing an outcry among lawmakers and the media in the Netherlands.
A fracas erupted earlier this week due to a shortage of Roche tests, which are used on equipment made by the company. However, testing facilities lack enough of a solution —lysis buffer, which is used to break open cells — but the company balked at making the formula available so that others could produce the solution and run tests.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
Very out of context, spelling etc – “Roche Tov!”